Sangeetha Balasubramanian, MD
Rheumatology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location · University Healthcare Alliance · 334 clinicians in this group
Looking this up.
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Balasubramanian’s office at (408) 357-1425 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A114316 · Current
Licensed to practise in California · since 2010 · expires 2028-07-31 · Bangalore University, Bangalore Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$470,197
Medicare paid this office $470,197 for 408 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 119 | $237,719 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $93,848 | None |
| Return visit (30+ min) | 342 | $77,818 | $114 |
| Long return visit (40+ min) | 128 | $29,902 | $156 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 274 | $7,789 | $15 |
See all 12 services
| Injection, denosumab, 1 mg | 119 | $237,719 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $93,848 | None |
| Return visit (30+ min) | 342 | $77,818 | $114 |
| Long return visit (40+ min) | 128 | $29,902 | $156 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 274 | $7,789 | $15 |
| Injection of drug or substance under skin or into muscle | 140 | $5,034 | $14 |
| New patient visit (60+ min) | 22 | $4,191 | $191 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 24 | $3,417 | $107 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,785 | $112 |
| Short return visit (20+ min) | 18 | $1,495 | $83 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 27 | $149 | None |
| Injection, methylprednisolone acetate, 1 mg | 11 | $88 | None |
Who their Medicare patients are
408 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 15% · Women 82% · Also on Medicaid 7% · Health risk score 1.39. Above the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 71% · Chronic kidney disease 28% · Diabetes 27% · Coronary heart disease 26% · Cancer 18% · Atrial fibrillation 16% · Depression 16% · Heart failure 13% · COPD 13% · Stroke 11% · Dementia 7%.
The office billed $2,131,310, Medicare allowed $603,308 and paid $470,197; for 41,045 services of 36 kinds; $335,179 of it was for drugs given in the office and $135,018 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 408 | 41,045 | 76 | 1.39 | $2,131,310 | $470,197 |
| 2023 | 403 | 37,908 | 76 | 1.35 | $2,246,390 | $501,393 |
| 2022 | 441 | 61,341 | 76 | 1.30 | $3,590,218 | $799,671 |
| 2021 | 467 | 64,550 | 75 | 1.26 | $3,897,412 | $881,914 |
| 2020 | 488 | 72,007 | 75 | 1.29 | $5,230,490 | $1,170,228 |
| 2019 | 440 | 48,885 | 75 | 1.31 | $3,942,469 | $944,047 |
| 2018 | 391 | 26,166 | 74 | 1.34 | $2,309,526 | $599,800 |
| 2017 | 352 | 27,144 | 74 | 1.34 | $2,475,807 | $653,380 |
| 2016 | 315 | 16,152 | 74 | 1.28 | $1,380,950 | $426,369 |
| 2015 | 228 | 12,174 | 73 | 1.38 | $599,756 | $229,739 |
| 2014 | 187 | 3,968 | 74 | 1.26 | $328,970 | $150,025 |
| 2013 | 194 | 4,390 | 73 | 1.20 | $224,122 | $136,385 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Injection, denosumab, 1 mg | 102 | $179,162 | None |
| Return visit (30+ min) | 326 | $69,655 | $112 |
| Long return visit (40+ min) | 158 | $35,709 | $156 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 27 | $4,279 | $116 |
| Injection of drug or substance under skin or into muscle | 126 | $3,780 | $14 |
| New patient visit (60+ min) | 20 | $3,593 | $180 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 26 | $3,211 | $67 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | $3,083 | $119 |
| Influenza vaccine split virus, preservative free | 25 | $1,798 | $72 |
| Administration of influenza virus vaccine | 26 | $961 | $37 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 33 | $216 | None |
2022: 19 services
| Injection, denosumab, 1 mg | 114 | $171,789 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13 | $138,449 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $116,759 | None |
| Injection, golimumab, 1 mg, for intravenous use | 16 | $87,967 | None |
| Return visit (30+ min) | 327 | $67,547 | $115 |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $61,013 | None |
| Long return visit (40+ min) | 167 | $45,904 | $159 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 42 | $10,123 | $73 |
| New patient visit (60+ min) | 39 | $7,364 | $189 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $7,124 | $145 |
| Injection of drug or substance under skin or into muscle | 141 | $4,742 | $14 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 27 | $4,602 | $107 |
| Telephone medical discussion with physician, 21-30 minutes | 34 | $4,324 | $92 |
| New patient visit (45+ min) | 12 | $1,769 | $147 |
| Administration of chemotherapy into vein, each additional hour | 12 | $1,432 | $30 |
| Short return visit (20+ min) | 12 | $1,053 | $88 |
| Influenza vaccine split virus, preservative free | 13 | $891 | $69 |
| Administration of influenza virus vaccine | 15 | $558 | $37 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 43 | $287 | None |
2021: 23 services
| Injection, denosumab, 1 mg | 111 | $153,386 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 20 | $144,046 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13 | $85,801 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $77,892 | None |
| Injection, tocilizumab, 1 mg | 18 | $69,982 | None |
| Injection, golimumab, 1 mg, for intravenous use | 17 | $67,431 | None |
| Return visit (30+ min) | 290 | $59,552 | $118 |
| Long return visit (40+ min) | 163 | $47,537 | $177 |
| Telephone medical discussion with physician, 21-30 minutes | 69 | $10,430 | $108 |
| New patient visit (60+ min) | 43 | $9,616 | $224 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 69 | $9,178 | $73 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $7,445 | $155 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 29 | $4,806 | $107 |
| Injection of drug or substance under skin or into muscle | 150 | $4,593 | $13 |
| Short return visit (20+ min) | 40 | $2,781 | $68 |
| Telephone medical discussion with physician, 11-20 minutes | 22 | $1,566 | $56 |
| Administration of chemotherapy into vein, each additional hour | 11 | $1,556 | $33 |
| Influenza vaccine split virus, preservative free | 21 | $1,305 | $62 |
| Injection, zoledronic acid, 1 mg | 15 | $571 | None |
| Injection into tendon or ligament | 11 | $557 | $46 |
| Administration of influenza virus vaccine | 24 | $516 | $22 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 48 | $352 | None |
| Injection, methylprednisolone acetate, 40 mg | 15 | $111 | None |
2020: 23 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $173,647 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 23 | $166,663 | None |
| Injection, golimumab, 1 mg, for intravenous use | 19 | $125,826 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $113,058 | None |
| Injection, denosumab, 1 mg | 79 | $112,399 | None |
| Injection, tocilizumab, 1 mg | 17 | $74,614 | None |
| Return visit (30+ min) | 259 | $46,288 | $95 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 78 | $13,223 | $73 |
| Short return visit (20+ min) | 121 | $11,690 | $68 |
| Telephone medical discussion with physician, 11-20 minutes | 102 | $9,865 | $71 |
| Administration of chemotherapy into vein, 1 hour or less | 18 | $9,294 | $145 |
| Telephone medical discussion with physician, 21-30 minutes | 63 | $9,020 | $104 |
| New patient visit (60+ min) | 34 | $6,820 | $201 |
| Long return visit (40+ min) | 38 | $6,746 | $130 |
| New patient visit (45+ min) | 38 | $5,310 | $140 |
| Injection of drug or substance under skin or into muscle | 124 | $3,962 | $13 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 26 | $3,446 | $93 |
| Administration of chemotherapy into vein, each additional hour | 17 | $1,987 | $32 |
| Aspiration and/or injection of fluid from large joint | 13 | $1,058 | $71 |
| Influenza vaccine split virus, preservative free | 17 | $1,012 | $60 |
| Injection, zoledronic acid, 1 mg | 17 | $679 | None |
| Administration of influenza virus vaccine | 19 | $396 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 47 | $328 | None |
2019: 19 services
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $134,012 | None |
| Injection, denosumab, 1 mg | 89 | $115,465 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 15 | $113,866 | None |
| Injection, golimumab, 1 mg, for intravenous use | 12 | $108,218 | None |
| Return visit (30+ min) | 288 | $62,997 | $94 |
| Short return visit (20+ min) | 135 | $11,547 | $65 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 41 | $8,517 | $72 |
| Administration of chemotherapy into vein, 1 hour or less | 15 | $7,674 | $142 |
| Long return visit (40+ min) | 45 | $6,313 | $121 |
| New patient visit (60+ min) | 34 | $6,063 | $178 |
| New patient visit (45+ min) | 41 | $5,537 | $135 |
| Injection of drug or substance under skin or into muscle | 121 | $4,011 | $15 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 28 | $3,530 | $93 |
| Aspiration and/or injection of fluid from large joint | 28 | $1,896 | $57 |
| Administration of chemotherapy into vein, each additional hour | 15 | $1,668 | $31 |
| Influenza vaccine split virus, preservative free | 14 | $768 | $55 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 60 | $489 | None |
| Administration of influenza virus vaccine | 18 | $369 | $21 |
| Injection, methylprednisolone acetate, 40 mg | 12 | $79 | None |
2018: 13 services
| Injection, denosumab, 1 mg | 65 | $81,454 | None |
| Return visit (30+ min) | 276 | $62,175 | $97 |
| Short return visit (20+ min) | 99 | $9,273 | $68 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $6,896 | $70 |
| New patient visit (45+ min) | 44 | $6,594 | $150 |
| New patient visit (60+ min) | 32 | $6,115 | $191 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 33 | $4,391 | $95 |
| Injection of drug or substance under skin or into muscle | 95 | $3,678 | $20 |
| Long return visit (40+ min) | 25 | $3,632 | $125 |
| Aspiration and/or injection of fluid from large joint | 20 | $1,308 | $50 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 12 | $706 | $20 |
| Short return visit | 15 | $682 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 58 | $550 | None |
2017: 16 services
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $280,587 | None |
| Return visit (30+ min) | 272 | $66,755 | $95 |
| Injection, denosumab, 1 mg | 49 | $61,601 | None |
| Short return visit (20+ min) | 104 | $9,986 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 28 | $9,484 | $68 |
| New patient visit (45+ min) | 49 | $7,017 | $143 |
| New patient visit (60+ min) | 32 | $6,078 | $190 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 31 | $4,377 | $89 |
| Long return visit (40+ min) | 29 | $4,092 | $120 |
| Injection of drug or substance under skin or into muscle | 63 | $3,538 | $24 |
| Aspiration and/or injection of fluid from large joint | 28 | $2,054 | $50 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $1,353 | $18 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 63 | $680 | None |
| Short return visit | 12 | $505 | $42 |
| Administration of influenza virus vaccine | 13 | $420 | $32 |
| X-ray of chest, 2 views, front and side | 15 | $270 | $18 |
2016: 18 services
| Injection, infliximab, excludes biosimilar, 10 mg | 14 | $179,455 | None |
| Return visit (30+ min) | 241 | $46,625 | $93 |
| Injection, denosumab, 1 mg | 34 | $29,809 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $11,018 | $74 |
| New patient visit (45+ min) | 63 | $9,057 | $144 |
| New patient visit (60+ min) | 44 | $8,335 | $189 |
| Long return visit (40+ min) | 46 | $7,134 | $127 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $6,630 | $69 |
| Short return visit (20+ min) | 55 | $4,392 | $65 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $4,338 | $140 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 19 | $2,627 | $94 |
| Administration of chemotherapy into vein, each additional hour | 12 | $1,672 | $28 |
| Injection of drug or substance under skin or into muscle | 41 | $1,368 | $25 |
| Aspiration and/or injection of fluid from large joint | 20 | $1,285 | $51 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $739 | $18 |
| Administration of influenza virus vaccine | 17 | $539 | $32 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 43 | $427 | None |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 11 | $130 | $12 |
2015: 13 services
| Return visit (30+ min) | 166 | $34,083 | $92 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $11,512 | $76 |
| Injection, denosumab, 1 mg | 13 | $9,227 | None |
| New patient visit (60+ min) | 42 | $7,990 | $190 |
| New patient visit (45+ min) | 41 | $6,137 | $150 |
| Short return visit (20+ min) | 37 | $3,735 | $66 |
| Long return visit (40+ min) | 24 | $3,468 | $120 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 14 | $3,282 | $86 |
| Aspiration and/or injection of fluid from large joint | 20 | $1,416 | $52 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 30 | $414 | None |
| Administration of influenza virus vaccine | 13 | $413 | $32 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 13 | $153 | $12 |
| Infusion, normal saline solution, 250 cc | 14 | $19 | None |
2014: 17 services
| Return visit (30+ min) | 153 | $38,808 | $91 |
| Insertion of needle or tube into artery of arm or leg | 14 | $9,878 | $274 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $9,750 | $66 |
| Short return visit (20+ min) | 47 | $5,794 | $66 |
| New patient visit (45+ min) | 38 | $5,605 | $144 |
| Ultrasonic guidance for needle placement | 31 | $5,106 | $72 |
| Aspiration and/or injection of fluid from large joint | 42 | $4,690 | $49 |
| Injection of drug or substance under skin or into muscle | 23 | $2,998 | $24 |
| Long return visit (40+ min) | 25 | $2,977 | $119 |
| New patient visit (60+ min) | 15 | $2,820 | $188 |
| Insertion of artery tube for prolonged infusion | 14 | $2,320 | $110 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $2,033 | $70 |
| Short return visit | 16 | $706 | $39 |
| Injection, methylprednisolone acetate, 40 mg | 35 | $264 | None |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 13 | $221 | None |
| Injection, triamcinolone hexacetonide, per 5 mg | 13 | $41 | None |
| Infusion, normal saline solution, 250 cc | 14 | $10 | None |
2013: 10 services
| Return visit (30+ min) | 143 | $29,566 | $90 |
| Administration of chemotherapy into vein, 1 hour or less | 16 | $6,903 | $147 |
| Short return visit (20+ min) | 58 | $4,788 | $59 |
| New patient visit (45+ min) | 31 | $4,558 | $147 |
| Aspiration and/or injection of fluid from large joint | 37 | $3,230 | $48 |
| Injection of drug or substance under skin or into muscle | 26 | $1,390 | $25 |
| Administration of chemotherapy into vein, each additional hour | 11 | $1,196 | $31 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 29 | $234 | None |
| Injection, methylprednisolone acetate, 40 mg | 15 | $101 | None |
| Infusion, normal saline solution, 250 cc | 16 | $9 | None |
Drugs they prescribed that Part D paid
$2,247,346
Pharmacies billed $2,247,346 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 9% of their Part D prescriptions (164 of 1,936) in 2024. Above the middle of the specialty; the typical rheumatology clinician is at 3%. Long-acting opioids: 10% of their opioid prescriptions.
1,576 generic and fewer than 11 brand-name prescriptions · $2,247,346 in drug cost · 17 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira(Cf) | 49 | $665,099 | $13,573 |
| Xeljanz Xr | 53 | $370,296 | $6,987 |
| Rinvoq | 26 | $264,120 | $10,158 |
| Cosentyx Sensoready | 15 | $169,967 | $11,331 |
| Tymlos | 31 | $98,069 | $3,164 |
See all 39 drugs
| Humira(Cf) | 49 | $665,099 | $13,573 |
| Xeljanz Xr | 53 | $370,296 | $6,987 |
| Rinvoq | 26 | $264,120 | $10,158 |
| Cosentyx Sensoready | 15 | $169,967 | $11,331 |
| Tymlos | 31 | $98,069 | $3,164 |
| Teriparatide | 15 | $31,872 | $2,125 |
| Prolia | 12 | $20,932 | $1,744 |
| Otrexup | 14 | $16,011 | $1,144 |
| Hydroxychloroquine Sulfate | 240 | $12,016 | $50 |
| Oxycontin | 12 | $5,563 | $464 |
| Leflunomide | 65 | $5,026 | $77 |
| Celecoxib | 50 | $4,862 | $97 |
| Diclofenac | 43 | $4,794 | $111 |
| Methotrexate | 119 | $4,453 | $37 |
| Lidocaine | 15 | $4,005 | $267 |
| Duloxetine | 93 | $1,956 | $21 |
| Prednisone | 168 | $1,828 | $11 |
| Febuxostat | 16 | $1,787 | $112 |
| Azathioprine | 29 | $1,597 | $55 |
| Cevimeline | 13 | $1,545 | $119 |
| Hydrocodone-Acetaminophen | 63 | $1,290 | $20 |
| Allopurinol | 73 | $1,120 | $15 |
| Pregabalin | 35 | $1,092 | $31 |
| Sulfasalazine | 31 | $801 | $26 |
| Leucovorin | 27 | $775 | $29 |
| Alendronate | 56 | $651 | $12 |
| Acetaminophen-Codeine | 27 | $645 | $24 |
| Famotidine | 35 | $631 | $18 |
| Oxycodone-Acetaminophen | 17 | $595 | $35 |
| Gabapentin | 39 | $540 | $14 |
| Baclofen | 52 | $507 | $10 |
| Folic Acid | 23 | $415 | $18 |
| Sertraline | 13 | $332 | $26 |
| Methylprednisolone | 17 | $280 | $16 |
| Cyclobenzaprine | 13 | $187 | $14 |
| Meloxicam | 25 | $186 | $7 |
| Ibuprofen | 13 | $160 | $12 |
| Tramadol | 34 | $155 | $5 |
| Pantoprazole | 12 | $58 | $5 |
Year by year
| 2024 | 1,936 | 335 | 9% (164) | None | $2,247,346 |
| 2023 | 1,945 | 335 | 8% (152) | None | $2,109,827 |
| 2022 | 1,878 | 313 | 7% (137) | 17% | $1,597,901 |
| 2021 | 2,017 | 310 | 9% (171) | 16% | $1,345,589 |
| 2020 | 2,152 | 286 | 8% (175) | 16% | $1,093,249 |
| 2019 | 2,111 | 318 | 8% (176) | 18% | $1,190,628 |
| 2018 | 2,218 | 290 | 8% (183) | 21% | $1,185,677 |
| 2017 | 2,191 | 253 | 9% (207) | 21% | $1,003,488 |
| 2016 | 1,991 | 255 | 7% (132) | 28% | $720,171 |
| 2015 | 1,787 | 227 | 5% (93) | 27% | $559,716 |
| 2014 | 1,934 | 196 | 7% (144) | 31% | $710,240 |
| 2013 | 1,969 | 189 | 10% (201) | None | $500,640 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 36 drugs
| Humira(Cf) | 31 | $462,725 | $14,927 |
| Xeljanz Xr | 43 | $315,325 | $7,333 |
| Rinvoq | 34 | $247,311 | $7,274 |
| Cosentyx Sensoready | 25 | $245,013 | $9,801 |
| Tymlos | 19 | $52,169 | $2,746 |
| Plaquenil | 14 | $23,752 | $1,697 |
| Prolia | 12 | $20,283 | $1,690 |
| Hydroxychloroquine Sulfate | 212 | $19,034 | $90 |
| Diclofenac | 70 | $8,156 | $117 |
| Leflunomide | 70 | $6,943 | $99 |
| Lidocaine | 13 | $6,941 | $534 |
| Celecoxib | 53 | $5,622 | $106 |
| Methotrexate | 130 | $5,008 | $39 |
| Oxycontin | 11 | $4,671 | $425 |
| Febuxostat | 22 | $4,649 | $211 |
| Prednisone | 165 | $2,223 | $13 |
| Pregabalin | 23 | $2,128 | $93 |
| Duloxetine | 74 | $2,072 | $28 |
| Allopurinol | 75 | $1,413 | $19 |
| Leucovorin | 45 | $1,398 | $31 |
| Hydrocodone-Acetaminophen | 51 | $1,363 | $27 |
| Azathioprine | 24 | $1,305 | $54 |
| Alendronate | 60 | $1,091 | $18 |
| Gabapentin | 67 | $1,034 | $15 |
| Sulfasalazine | 37 | $1,034 | $28 |
| Cevimeline | 11 | $957 | $87 |
| Baclofen | 51 | $699 | $14 |
| Famotidine | 26 | $628 | $24 |
| Tramadol | 51 | $614 | $12 |
| Sertraline | 21 | $565 | $27 |
| Acetaminophen-Codeine | 22 | $380 | $17 |
| Methylprednisolone | 11 | $192 | $17 |
| Meloxicam | 24 | $180 | $8 |
| Lorazepam | 13 | $120 | $9 |
| Pantoprazole | 15 | $109 | $7 |
| Folic Acid | 35 | $108 | $3 |
2022: 42 drugs
| Humira(Cf) | 23 | $322,190 | $14,008 |
| Cosentyx | 22 | $297,693 | $13,531 |
| Xeljanz Xr | 38 | $280,147 | $7,372 |
| Enbrel Sureclick | 13 | $90,377 | $6,952 |
| Rinvoq | 13 | $82,749 | $6,365 |
| Tymlos | 14 | $34,338 | $2,453 |
| Plaquenil | 18 | $23,165 | $1,287 |
| Hydroxychloroquine Sulfate | 223 | $20,945 | $94 |
| Prolia | 12 | $18,511 | $1,543 |
| Otrexup | 14 | $15,367 | $1,098 |
| Lidocaine | 15 | $10,459 | $697 |
| Leflunomide | 69 | $9,364 | $136 |
| Febuxostat | 25 | $8,282 | $331 |
| Celecoxib | 57 | $7,118 | $125 |
| Methotrexate | 171 | $7,077 | $41 |
| Duloxetine | 77 | $6,728 | $87 |
| Diclofenac | 49 | $5,233 | $107 |
| Oxycontin | 11 | $4,893 | $445 |
| Azathioprine | 30 | $3,309 | $110 |
| Prednisone | 151 | $2,099 | $14 |
| Sulfasalazine | 42 | $1,754 | $42 |
| Pregabalin | 16 | $1,571 | $98 |
| Leucovorin | 50 | $1,541 | $31 |
| Methylprednisolone | 15 | $1,499 | $100 |
| Hydrocodone-Acetaminophen | 38 | $1,246 | $33 |
| Baclofen | 47 | $979 | $21 |
| Gabapentin | 36 | $923 | $26 |
| Famotidine | 30 | $845 | $28 |
| Allopurinol | 52 | $831 | $16 |
| Acetaminophen-Codeine | 29 | $825 | $28 |
| Tramadol | 39 | $727 | $19 |
| Alendronate | 56 | $670 | $12 |
| Sulfasalazine Dr | 13 | $667 | $51 |
| Sertraline | 14 | $469 | $34 |
| Promethazine | 12 | $249 | $21 |
| Folic Acid | 35 | $235 | $7 |
| Meloxicam | 24 | $221 | $9 |
| Omeprazole | 11 | $170 | $15 |
| Oxycodone-Acetaminophen | 11 | $162 | $15 |
| Pantoprazole | 12 | $137 | $11 |
| Ibuprofen | 14 | $113 | $8 |
| Insulin | 12 | $73 | $6 |
2021: 41 drugs
| Xeljanz Xr | 47 | $315,058 | $6,703 |
| Humira(Cf) | 17 | $209,332 | $12,314 |
| Cosentyx | 11 | $108,422 | $9,857 |
| Rinvoq | 18 | $103,143 | $5,730 |
| Benlysta | 12 | $51,011 | $4,251 |
| Plaquenil | 24 | $22,403 | $933 |
| Hydroxychloroquine Sulfate | 205 | $19,857 | $97 |
| Otrexup | 17 | $11,063 | $651 |
| Diclofenac | 92 | $10,669 | $116 |
| Leflunomide | 65 | $10,018 | $154 |
| Febuxostat | 29 | $7,249 | $250 |
| Methotrexate | 140 | $6,977 | $50 |
| Celecoxib | 72 | $6,458 | $90 |
| Duloxetine | 104 | $5,507 | $53 |
| Oxycontin | 12 | $4,971 | $414 |
| Lidocaine | 15 | $4,509 | $301 |
| Cevimeline | 11 | $3,389 | $308 |
| Azathioprine | 35 | $2,844 | $81 |
| Prednisone | 152 | $1,973 | $13 |
| Sulfasalazine | 39 | $1,440 | $37 |
| Methylprednisolone | 16 | $1,308 | $82 |
| Hydrocodone-Acetaminophen | 40 | $1,077 | $27 |
| Baclofen | 68 | $1,026 | $15 |
| Pregabalin | 16 | $1,025 | $64 |
| Acetaminophen-Codeine | 24 | $1,007 | $42 |
| Gabapentin | 48 | $863 | $18 |
| Alendronate | 69 | $831 | $12 |
| Famotidine | 24 | $827 | $34 |
| Tramadol | 71 | $817 | $12 |
| Allopurinol | 48 | $802 | $17 |
| Leucovorin | 34 | $680 | $20 |
| Sulfasalazine Dr | 13 | $663 | $51 |
| Sertraline | 21 | $545 | $26 |
| Oxycodone | 12 | $417 | $35 |
| Oxycodone-Acetaminophen | 12 | $365 | $30 |
| Pantoprazole | 18 | $304 | $17 |
| Methotrexate | 14 | $266 | $19 |
| Triamcinolone Acetonide | 12 | $231 | $19 |
| Meloxicam | 26 | $183 | $7 |
| Folic Acid | 27 | $140 | $5 |
| Ibuprofen | 16 | $100 | $6 |
2020: 41 drugs
| Xeljanz Xr | 20 | $192,202 | $9,610 |
| Humira(Cf) | 15 | $128,814 | $8,588 |
| Xeljanz | 22 | $108,974 | $4,953 |
| Hydroxychloroquine Sulfate | 254 | $28,462 | $112 |
| Prolia | 12 | $15,586 | $1,299 |
| Leflunomide | 69 | $14,090 | $204 |
| Diclofenac | 127 | $13,263 | $104 |
| Plaquenil | 14 | $8,226 | $588 |
| Lidocaine | 19 | $7,131 | $375 |
| Febuxostat | 15 | $6,251 | $417 |
| Methotrexate | 144 | $5,975 | $41 |
| Cevimeline | 23 | $5,038 | $219 |
| Oxycontin | 13 | $4,630 | $356 |
| Prednisone | 256 | $3,597 | $14 |
| Duloxetine | 93 | $3,422 | $37 |
| Celecoxib | 48 | $3,366 | $70 |
| Mycophenolate Mofetil | 25 | $3,194 | $128 |
| Ibandronate | 14 | $1,794 | $128 |
| Sulfasalazine | 37 | $1,638 | $44 |
| Azathioprine | 22 | $1,584 | $72 |
| Hydrocodone-Acetaminophen | 45 | $1,386 | $31 |
| Acetaminophen-Codeine | 36 | $1,204 | $33 |
| Alendronate | 70 | $1,171 | $17 |
| Pregabalin | 14 | $1,062 | $76 |
| Baclofen | 61 | $1,062 | $17 |
| Allopurinol | 55 | $1,019 | $19 |
| Methylprednisolone | 18 | $948 | $53 |
| Gabapentin | 45 | $607 | $13 |
| Leucovorin | 28 | $490 | $18 |
| Venlafaxine Hcl Er | 20 | $434 | $22 |
| Oxycodone | 12 | $421 | $35 |
| Sertraline | 23 | $376 | $16 |
| Methotrexate | 20 | $351 | $18 |
| Naproxen | 15 | $333 | $22 |
| Zolpidem Tartrate Er | 11 | $267 | $24 |
| Tramadol | 54 | $250 | $5 |
| Meloxicam | 30 | $218 | $7 |
| Pantoprazole | 23 | $204 | $9 |
| Omeprazole | 11 | $125 | $11 |
| Cyclobenzaprine | 16 | $120 | $7 |
| Insulin | 12 | $65 | $5 |
2019: 46 drugs
| Stelara | 11 | $251,306 | $22,846 |
| Humira(Cf) | 13 | $113,460 | $8,728 |
| Enbrel Sureclick | 13 | $108,986 | $8,384 |
| Xeljanz | 23 | $105,117 | $4,570 |
| Cimzia | 12 | $72,539 | $6,045 |
| Forteo | 11 | $54,091 | $4,917 |
| Tymlos | 12 | $38,183 | $3,182 |
| Lidoderm | 18 | $30,287 | $1,683 |
| Hydroxychloroquine Sulfate | 229 | $29,653 | $129 |
| Diclofenac | 97 | $13,781 | $142 |
| Leflunomide | 45 | $13,571 | $302 |
| Methotrexate | 226 | $8,975 | $40 |
| Uloric | 11 | $7,322 | $666 |
| Plaquenil | 12 | $6,832 | $569 |
| Voltaren | 23 | $5,470 | $238 |
| Lidocaine | 12 | $4,271 | $356 |
| Mycophenolate Mofetil | 19 | $4,042 | $213 |
| Oxycontin | 12 | $3,957 | $330 |
| Duloxetine | 81 | $3,723 | $46 |
| Mycophenolic Acid | 14 | $3,690 | $264 |
| Cevimeline | 20 | $2,811 | $141 |
| Prednisone | 216 | $2,418 | $11 |
| Celecoxib | 39 | $2,376 | $61 |
| Acetaminophen-Codeine | 36 | $1,559 | $43 |
| Hydrocodone-Acetaminophen | 49 | $1,478 | $30 |
| Azathioprine | 27 | $1,420 | $53 |
| Sulfasalazine | 26 | $1,311 | $50 |
| Leucovorin | 68 | $1,163 | $17 |
| Methylprednisolone | 21 | $1,029 | $49 |
| Baclofen | 52 | $956 | $18 |
| Gabapentin | 36 | $872 | $24 |
| Allopurinol | 46 | $865 | $19 |
| Tramadol | 63 | $660 | $10 |
| Alendronate | 44 | $395 | $9 |
| Sertraline | 24 | $383 | $16 |
| Methotrexate | 20 | $349 | $17 |
| Naproxen | 16 | $240 | $15 |
| Venlafaxine Hcl Er | 13 | $234 | $18 |
| Meloxicam | 22 | $191 | $9 |
| Cyclobenzaprine | 15 | $183 | $12 |
| Ranitidine | 17 | $146 | $9 |
| Pantoprazole | 18 | $122 | $7 |
| Insulin | 20 | $91 | $5 |
| Zolpidem | 13 | $87 | $7 |
| Furosemide | 15 | $83 | $6 |
| Omeprazole | 11 | $21 | $2 |
2018: 44 drugs
| Humira | 22 | $163,854 | $7,448 |
| Xeljanz Xr | 16 | $161,576 | $10,098 |
| Xeljanz | 36 | $148,015 | $4,112 |
| Forteo | 19 | $90,065 | $4,740 |
| Enbrel | 15 | $73,466 | $4,898 |
| Cimzia | 12 | $49,440 | $4,120 |
| Hydroxychloroquine Sulfate | 240 | $36,112 | $150 |
| Prolia | 11 | $12,899 | $1,173 |
| Methotrexate | 249 | $12,356 | $50 |
| Leflunomide | 41 | $11,015 | $269 |
| Voltaren | 44 | $9,625 | $219 |
| Diclofenac | 62 | $8,111 | $131 |
| Lidocaine | 17 | $7,711 | $454 |
| Uloric | 13 | $6,316 | $486 |
| Cevimeline | 28 | $3,716 | $133 |
| Duloxetine | 74 | $3,383 | $46 |
| Oxycontin | 11 | $3,296 | $300 |
| Celecoxib | 50 | $2,511 | $50 |
| Prednisone | 241 | $2,490 | $10 |
| Azathioprine | 41 | $2,193 | $53 |
| Hydrocodone-Acetaminophen | 58 | $1,972 | $34 |
| Gabapentin | 46 | $1,594 | $35 |
| Acetaminophen-Codeine | 37 | $1,435 | $39 |
| Sulfasalazine | 31 | $1,355 | $44 |
| Leucovorin | 66 | $1,344 | $20 |
| Fentanyl | 18 | $1,276 | $71 |
| Allopurinol | 53 | $882 | $17 |
| Methylprednisolone | 17 | $826 | $49 |
| Baclofen | 61 | $766 | $13 |
| Tramadol | 53 | $635 | $12 |
| Cyclobenzaprine | 22 | $612 | $28 |
| Alendronate | 49 | $512 | $10 |
| Lorazepam | 16 | $503 | $31 |
| Methotrexate | 30 | $392 | $13 |
| Sertraline | 34 | $303 | $9 |
| Naproxen | 20 | $297 | $15 |
| Risedronate | 11 | $279 | $25 |
| Ranitidine | 21 | $255 | $12 |
| Meloxicam | 38 | $154 | $4 |
| Venlafaxine Hcl Er | 11 | $145 | $13 |
| Pantoprazole | 12 | $134 | $11 |
| Insulin | 16 | $102 | $6 |
| Zolpidem | 14 | $99 | $7 |
| Omeprazole | 13 | $57 | $4 |
2017: 44 drugs
| Xeljanz | 29 | $111,415 | $3,842 |
| Xeljanz Xr | 17 | $108,174 | $6,363 |
| Humira | 11 | $107,063 | $9,733 |
| Cimzia | 14 | $81,438 | $5,817 |
| Simponi | 12 | $76,957 | $6,413 |
| Enbrel | 17 | $75,817 | $4,460 |
| Enbrel Sureclick | 12 | $71,935 | $5,995 |
| Forteo | 16 | $47,178 | $2,949 |
| Hydroxychloroquine Sulfate | 236 | $42,846 | $182 |
| Lidocaine | 29 | $14,425 | $497 |
| Lidoderm | 12 | $14,106 | $1,175 |
| Methotrexate | 251 | $13,004 | $52 |
| Voltaren | 50 | $11,734 | $235 |
| Mycophenolate Mofetil | 14 | $9,538 | $681 |
| Diclofenac | 62 | $9,072 | $146 |
| Uloric | 17 | $8,619 | $507 |
| Leflunomide | 24 | $6,663 | $278 |
| Celecoxib | 54 | $5,163 | $96 |
| Cevimeline | 34 | $5,134 | $151 |
| Risedronate | 21 | $3,429 | $163 |
| Duloxetine | 76 | $3,310 | $44 |
| Prednisone | 262 | $2,971 | $11 |
| Hydrocodone-Acetaminophen | 80 | $2,311 | $29 |
| Azathioprine | 39 | $2,160 | $55 |
| Sulfasalazine | 43 | $1,754 | $41 |
| Fentanyl | 24 | $1,535 | $64 |
| Methylprednisolone | 15 | $1,236 | $82 |
| Leucovorin | 51 | $1,145 | $22 |
| Allopurinol | 42 | $976 | $23 |
| Acetaminophen-Codeine | 40 | $840 | $21 |
| Gabapentin | 40 | $643 | $16 |
| Lorazepam | 26 | $542 | $21 |
| Baclofen | 56 | $466 | $8 |
| Tramadol | 50 | $401 | $8 |
| Alendronate | 39 | $388 | $10 |
| Methotrexate | 23 | $261 | $11 |
| Naproxen | 19 | $247 | $13 |
| Fluoxetine | 11 | $217 | $20 |
| Cyclobenzaprine | 16 | $195 | $12 |
| Venlafaxine Hcl Er | 16 | $170 | $11 |
| Meloxicam | 45 | $160 | $4 |
| Sertraline | 24 | $88 | $4 |
| Insulin | 17 | $75 | $4 |
| Furosemide | 12 | $52 | $4 |
2016: 38 drugs
| Enbrel | 29 | $186,364 | $6,426 |
| Xeljanz | 19 | $70,717 | $3,722 |
| Humira | 13 | $54,223 | $4,171 |
| Forteo | 20 | $49,782 | $2,489 |
| Hydroxychloroquine Sulfate | 290 | $44,348 | $153 |
| Actemra | 14 | $43,691 | $3,121 |
| Lidocaine | 52 | $29,447 | $566 |
| Methotrexate | 262 | $11,873 | $45 |
| Voltaren | 47 | $9,587 | $204 |
| Uloric | 24 | $8,022 | $334 |
| Celecoxib | 46 | $5,026 | $109 |
| Diclofenac | 38 | $3,753 | $99 |
| Duloxetine | 62 | $3,518 | $57 |
| Leflunomide | 26 | $3,469 | $133 |
| Prednisone | 223 | $2,652 | $12 |
| Colchicine | 20 | $2,471 | $124 |
| Acetaminophen-Codeine | 38 | $1,628 | $43 |
| Mycophenolate Mofetil | 12 | $1,546 | $129 |
| Fentanyl | 16 | $1,384 | $87 |
| Hydrocodone-Acetaminophen | 42 | $1,278 | $30 |
| Leucovorin | 57 | $1,170 | $21 |
| Cevimeline | 15 | $1,092 | $73 |
| Allopurinol | 39 | $930 | $24 |
| Gabapentin | 48 | $905 | $19 |
| Sulfasalazine | 21 | $813 | $39 |
| Azathioprine | 23 | $697 | $30 |
| Naproxen | 37 | $452 | $12 |
| Alendronate | 50 | $395 | $8 |
| Methylprednisolone | 11 | $383 | $35 |
| Methotrexate | 21 | $304 | $14 |
| Baclofen | 27 | $277 | $10 |
| Tramadol | 35 | $257 | $7 |
| Meloxicam | 48 | $194 | $4 |
| Venlafaxine Hcl Er | 14 | $175 | $13 |
| Lorazepam | 11 | $171 | $16 |
| Ranitidine | 16 | $86 | $5 |
| Insulin | 21 | $68 | $3 |
| Sertraline | 12 | $67 | $6 |
2015: 32 drugs
| Humira | 31 | $152,449 | $4,918 |
| Enbrel | 24 | $77,376 | $3,224 |
| Xeljanz | 15 | $40,128 | $2,675 |
| Actemra | 17 | $36,759 | $2,162 |
| Hydroxychloroquine Sulfate | 240 | $34,836 | $145 |
| Forteo | 18 | $34,764 | $1,931 |
| Lidocaine | 36 | $23,876 | $663 |
| Lidoderm | 22 | $18,635 | $847 |
| Voltaren | 69 | $16,502 | $239 |
| Methotrexate | 250 | $14,890 | $60 |
| Duloxetine | 70 | $6,554 | $94 |
| Uloric | 16 | $3,971 | $248 |
| Celecoxib | 28 | $3,963 | $142 |
| Prednisone | 234 | $2,662 | $11 |
| Acetaminophen-Codeine | 45 | $1,524 | $34 |
| Colchicine | 13 | $1,482 | $114 |
| Azathioprine | 29 | $1,237 | $43 |
| Leflunomide | 12 | $1,178 | $98 |
| Allopurinol | 41 | $963 | $23 |
| Sulfasalazine | 26 | $745 | $29 |
| Gabapentin | 58 | $714 | $12 |
| Leucovorin | 39 | $626 | $16 |
| Hydrocodone-Acetaminophen | 21 | $481 | $23 |
| Naproxen | 44 | $404 | $9 |
| Baclofen | 55 | $343 | $6 |
| Methotrexate | 14 | $246 | $18 |
| Meloxicam | 41 | $190 | $5 |
| Tramadol | 19 | $161 | $8 |
| Alendronate | 22 | $151 | $7 |
| Venlafaxine Hcl Er | 12 | $120 | $10 |
| Ranitidine | 13 | $86 | $7 |
| Insulin | 15 | $47 | $3 |
2014: 33 drugs
| Enbrel | 41 | $109,211 | $2,664 |
| Cimzia | 31 | $97,416 | $3,142 |
| Actemra | 41 | $73,724 | $1,798 |
| Humira | 26 | $71,397 | $2,746 |
| Forteo | 31 | $53,137 | $1,714 |
| Lidoderm | 36 | $31,666 | $880 |
| Lidocaine | 41 | $29,792 | $727 |
| Methotrexate | 262 | $17,494 | $67 |
| Voltaren | 80 | $17,290 | $216 |
| Celebrex | 50 | $14,333 | $287 |
| Prolia | 15 | $13,204 | $880 |
| Duloxetine | 57 | $7,965 | $140 |
| Hydroxychloroquine Sulfate | 243 | $6,542 | $27 |
| Colcrys | 21 | $3,351 | $160 |
| Lovaza | 11 | $2,511 | $228 |
| Cymbalta | 11 | $2,392 | $217 |
| Hydrocodone-Acetaminophen | 55 | $1,891 | $34 |
| Prednisone | 181 | $1,640 | $9 |
| Acetaminophen-Codeine | 55 | $1,455 | $26 |
| Azathioprine | 48 | $1,366 | $28 |
| Sulfasalazine | 35 | $876 | $25 |
| Gabapentin | 36 | $835 | $23 |
| Allopurinol | 53 | $579 | $11 |
| Omeprazole | 41 | $490 | $12 |
| Bd Ultra-Fine Pen Needle | 12 | $431 | $36 |
| Methylprednisolone | 14 | $406 | $29 |
| Leucovorin | 30 | $359 | $12 |
| Baclofen | 60 | $309 | $5 |
| Naproxen | 41 | $300 | $7 |
| Venlafaxine Hcl Er | 15 | $280 | $19 |
| Meloxicam | 24 | $265 | $11 |
| Tramadol | 24 | $144 | $6 |
| Alendronate | 12 | $80 | $7 |
2013: 32 drugs
| Remicade | 28 | $97,428 | $3,480 |
| Enbrel | 39 | $92,017 | $2,359 |
| Lidoderm | 57 | $56,396 | $989 |
| Humira | 24 | $55,855 | $2,327 |
| Cimzia | 12 | $38,671 | $3,223 |
| Methotrexate | 309 | $18,287 | $59 |
| Forteo | 13 | $16,877 | $1,298 |
| Cymbalta | 60 | $14,719 | $245 |
| Celebrex | 53 | $11,942 | $225 |
| Voltaren | 76 | $11,553 | $152 |
| Colcrys | 30 | $5,479 | $183 |
| Meprobamate | 16 | $3,580 | $224 |
| Hydroxychloroquine Sulfate | 188 | $3,478 | $18 |
| Lyrica | 13 | $3,456 | $266 |
| Lovaza | 11 | $2,308 | $210 |
| Acetaminophen-Codeine | 70 | $1,958 | $28 |
| Hydrocodone-Acetaminophen | 70 | $1,297 | $19 |
| Prednisone | 140 | $1,196 | $9 |
| Gabapentin | 50 | $605 | $12 |
| Naproxen | 62 | $601 | $10 |
| Azathioprine | 22 | $591 | $27 |
| Omeprazole | 49 | $584 | $12 |
| Sulfasalazine | 21 | $514 | $24 |
| Meloxicam | 51 | $486 | $10 |
| Cyclobenzaprine | 29 | $444 | $15 |
| Tramadol | 36 | $399 | $11 |
| Allopurinol | 53 | $391 | $7 |
| Venlafaxine Hcl Er | 15 | $366 | $24 |
| Baclofen | 40 | $198 | $5 |
| Propranolol | 11 | $147 | $13 |
| Folic Acid | 30 | $141 | $5 |
| Methocarbamol | 20 | $124 | $6 |
Money from drug and device companies
$36 in 2019
A payment is not proof that care is biased.
| Ucb | Cimzia | $36 | 1 payment
|
See the published payment
| Ucb | Education · 2019-02-11 | Cimzia | $36 |
Professional record
- NPI
- 1265640874
- Licence
- CA A114316California A114316: Current · expires 2028-07-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
- Mailing address
- 50 E Hamilton Ave Ste 200, Campbell, CA, 95008
- NPI first listed
- 2007-05-18
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 700 W Parr Ave Ste A, Los Gatos, CA, 95032